GROWTH-INHIBITION OF HUMAN COLORECTAL-CARCINOMA CELLS BY INTERLEUKIN-4 AND EXPRESSION OF FUNCTIONAL INTERLEUKIN-4 RECEPTORS

被引:31
作者
LAHM, H
SCHNYDER, B
WYNIGER, J
BORBENYI, Z
YILMAZ, A
CAR, BD
FISCHER, JR
GIVEL, JC
RYFFEL, B
机构
[1] SWISS FED INST TECHNOL,INST TOXICOL,CH-8603 SCHWERZENBACH,SWITZERLAND
[2] UNIV ZURICH,CH-8603 SCHWERZENBACH,SWITZERLAND
[3] ALBERT SZENT GYORGYI UNIV,SCH MED,DEPT MED 2,H-6701 SZEGED,HUNGARY
[4] THORAX HOSP,DEPT MED ONCOL,D-69126 HEIDELBERG,GERMANY
[5] CHU VAUDOIS,DEPT SURG,CH-1011 LAUSANNE,SWITZERLAND
关键词
D O I
10.1002/ijc.2910590325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The growth-inhibitory effect of interleukin-4 (IL-4) was investigated in a panel of 7 human colorectal-carcinoma cell lines. In 5 cell lines (HT29, WiDr, LS411N, LS513, LS1034) a dose-dependent reduction of proliferation was documented. At 100 U/ml, IL-4 inhibited thymidine incorporation between 45 and 75% and MTT conversion (26 to 41%). The ability of LS513 and WiDr cells to form colonies after IL-4 treatment was reduced by 85 and 62% respectively. LS513 was the most sensitive cell line, with IL-4 inducing half-maximal inhibition at 5 to 6 U/ml. The inhibitory effect of IL-4 was completely neutralized by anti-IL-4 antibodies. Northern-blot analysis revealed the presence of IL-4-receptor (IL-4R) mRNA in all cell lines. The membrane expression of the 130-kDa IL-4R was assessed by FACS, utilizing an anti-IL-4R binding. Our results attribute an important role for IL-4 as a negative regulator of colorectal-carcinoma cell growth, thus indicating a possible avenue for intervention in this disease. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:440 / 447
页数:8
相关论文
共 41 条
[11]   IDENTIFICATION OF INTERLEUKIN-4 RECEPTOR-ASSOCIATED PROTEINS AND EXPRESSION OF BOTH HIGH-AFFINITY AND LOW-AFFINITY BINDING ON HUMAN LYMPHOID-CELLS [J].
FOXWELL, BMJ ;
WOERLY, G ;
RYFFEL, B .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (09) :1637-1641
[12]  
GALIZZI JP, 1989, J BIOL CHEM, V264, P6984
[13]   MOLECULAR-CLONING OF A CDNA-ENCODING THE HUMAN INTERLEUKIN-4 RECEPTOR [J].
GALIZZI, JP ;
ZUBER, CE ;
HARADA, N ;
GORMAN, DM ;
DJOSSOU, O ;
KASTELEIN, R ;
BANCHEREAU, J ;
HOWARD, M ;
MIYAJIMA, A .
INTERNATIONAL IMMUNOLOGY, 1990, 2 (07) :669-675
[14]   RECOMBINANT HUMAN INTERLEUKIN-4 (IL-4) GIVEN AS DAILY SUBCUTANEOUS INJECTIONS - A PHASE-I DOSE TOXICITY TRIAL [J].
GILLEECE, MH ;
SCARFFE, JH ;
GHOSH, A ;
HEYWORTH, CM ;
BONNEM, E ;
TESTA, N ;
STERN, P ;
DEXTER, TM .
BRITISH JOURNAL OF CANCER, 1992, 66 (01) :204-210
[15]  
HARADA N, 1992, J BIOL CHEM, V267, P22752
[16]  
HOON DSB, 1991, CANCER RES, V51, P2002
[17]   IDENTIFICATION OF A T-CELL-DERIVED B-CELL GROWTH-FACTOR DISTINCT FROM INTERLEUKIN-2 [J].
HOWARD, M ;
FARRAR, J ;
HILFIKER, M ;
JOHNSON, B ;
TAKATSU, K ;
HAMAOKA, T ;
PAUL, WE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (03) :914-923
[18]   HUMAN INTERLEUKIN-4 RECEPTOR CONFERS BIOLOGICAL RESPONSIVENESS AND DEFINES A NOVEL RECEPTOR SUPERFAMILY [J].
IDZERDA, RL ;
MARCH, CJ ;
MOSLEY, B ;
LYMAN, SD ;
VANDENBOS, T ;
GIMPEL, SD ;
DIN, WS ;
GRABSTEIN, KH ;
WIDMER, MB ;
PARK, LS ;
COSMAN, D ;
BECKMANN, MP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (03) :861-873
[19]  
JELINEK DF, 1988, J IMMUNOL, V141, P164
[20]   INTERLEUKIN-4 RECEPTOR AND EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION IN COLORECTAL-CANCER [J].
KAKLAMANIS, L ;
GATTER, KC ;
MORTENSEN, N ;
HARRIS, AL .
BRITISH JOURNAL OF CANCER, 1992, 66 (04) :712-716